Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00838955 · ClinicalTrials.gov registry record · Phase 2
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
A Phase 2 study, sponsored by Loyola University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00838955: Clinical Trial Phase 2 study, sponsored by Loyola University.
NCT00838955 is a Phase 2 study that was terminated before completion, run by Loyola University. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00838955, a Phase 2 study, was terminated before completion, sponsored by Loyola University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This clinical trial is for patients with Hodgkin Lymphoma that has not responded to standard treatment. The purpose of this study is to determine what effects, good or bad, Temsirolimus has on Hodgkin Lymphoma. The study will also determine whether Temsirolimus is tolerated in patients with Hodgkin Lymphoma who have been previously treated with chemotherapy.
Primary Outcome
To estimate the overall response rate (complete or partial response and stable disease by the IWG criteria) to temsirolimus
Interventions
- DRUG Temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2009-01 |
| Est. Completion | 2017-10 |
| Phase | Phase 2 |
Why NCT00838955 stopped before completion
NCT00838955 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which Temsirolimus is the first listed.
NCT00838955 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00838955 about?
NCT00838955 is a clinical study titled "Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma". This clinical trial is for patients with Hodgkin Lymphoma that has not responded to standard treatment. The purpose of this study is to determine what effects, good or bad, Temsirolimus has on Hodgkin Lymphoma. The study will also determine whether Temsirolimus is tolerated in patients with Hodgkin ...
What is the current status of trial NCT00838955?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2009-01. Estimated completion is 2017-10.
What interventions are being tested in trial NCT00838955?
The interventions under investigation include: Temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00838955?
This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00838955's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia